Using PET 18F-FDG, 11CO, and 15O-water for monitoring prostate cancer during a phase II anti-angiogenic drug trial with thalidomide

K. A. Kurdziel, S. L. Bacharach, J. A. Carrasquillo, S. Huebsch, M. Whatley, D. Sellers, S. Steinberg, S. K. Libutti, J. Pluda, E. Reed, W. Dahut, W. D. Figg

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Assessing prostate metastases is difficult with conventional radiographic modalities as few patients have soft tissue involvement and most have only bone lesions. Even with FDG PET, problems due to decreased avidity compared to other tumor types can occur. We assessed PET's ability to monitor changes in such tumors during an anti-angiogenic therapy. We measured changes in tumor blood flow (15O), blood volume (11CO), 18F-FDG uptake and "metabolic volume" before and during thalidomide treatment, to see if these changes correlated with changes in PSA values. Six patients with androgen-independent prostate cancer were imaged with 18F-FDG, 11CO, and 15O water before and during (mean interval 63 days, range 55-76 days) thalidomide therapy (200-1200mg/day). Lesions were visually identified on FDG images (9 bone, 5 soft tissue lesions). VOI's were generated by 3D region growing, with a 50% maximum pixel threshold. These VOI's were registered with, and applied to, the 11CO and water studies. Correlations with PSA values were done using the Spearman rank test. The change in maximum (r = 0.77, P = 0.06) and mean FDG value (r = 0.83, P = 0.03), functional FDG volume (r = 0.66, P = 0.14), and 11-CO blood volume (r = 0.77, P = 0.06) all correlated with the change in PSA. Changes in blood flow values were smaller than the variance of the method for repeated measures, likely due to low flow values in bone. Changes in blood volume measured by 11CO, and the mean and peak activity and functional volume measured by 18F-FDG, correlate with changes in PSA and may be useful in monitoring anti-angiogenic therapy in prostate cancer.

Original languageEnglish (US)
Pages (from-to)144
Number of pages1
JournalClinical Positron Imaging (Netherlands)
Volume3
Issue number4
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Thalidomide
Angiogenesis Inhibitors
Fluorodeoxyglucose F18
Prostatic Neoplasms
Blood Volume
Water
Bone and Bones
Neoplasms
Therapeutics
Carbon Monoxide
Androgens
Prostate
Neoplasm Metastasis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Using PET 18F-FDG, 11CO, and 15O-water for monitoring prostate cancer during a phase II anti-angiogenic drug trial with thalidomide. / Kurdziel, K. A.; Bacharach, S. L.; Carrasquillo, J. A.; Huebsch, S.; Whatley, M.; Sellers, D.; Steinberg, S.; Libutti, S. K.; Pluda, J.; Reed, E.; Dahut, W.; Figg, W. D.

In: Clinical Positron Imaging (Netherlands), Vol. 3, No. 4, 2000, p. 144.

Research output: Contribution to journalArticle

Kurdziel, KA, Bacharach, SL, Carrasquillo, JA, Huebsch, S, Whatley, M, Sellers, D, Steinberg, S, Libutti, SK, Pluda, J, Reed, E, Dahut, W & Figg, WD 2000, 'Using PET 18F-FDG, 11CO, and 15O-water for monitoring prostate cancer during a phase II anti-angiogenic drug trial with thalidomide', Clinical Positron Imaging (Netherlands), vol. 3, no. 4, pp. 144. https://doi.org/10.1016/S1095-0397(00)00056-X
Kurdziel, K. A. ; Bacharach, S. L. ; Carrasquillo, J. A. ; Huebsch, S. ; Whatley, M. ; Sellers, D. ; Steinberg, S. ; Libutti, S. K. ; Pluda, J. ; Reed, E. ; Dahut, W. ; Figg, W. D. / Using PET 18F-FDG, 11CO, and 15O-water for monitoring prostate cancer during a phase II anti-angiogenic drug trial with thalidomide. In: Clinical Positron Imaging (Netherlands). 2000 ; Vol. 3, No. 4. pp. 144.
@article{e77508b84f7e4425a3e754b758191a96,
title = "Using PET 18F-FDG, 11CO, and 15O-water for monitoring prostate cancer during a phase II anti-angiogenic drug trial with thalidomide",
abstract = "Assessing prostate metastases is difficult with conventional radiographic modalities as few patients have soft tissue involvement and most have only bone lesions. Even with FDG PET, problems due to decreased avidity compared to other tumor types can occur. We assessed PET's ability to monitor changes in such tumors during an anti-angiogenic therapy. We measured changes in tumor blood flow (15O), blood volume (11CO), 18F-FDG uptake and {"}metabolic volume{"} before and during thalidomide treatment, to see if these changes correlated with changes in PSA values. Six patients with androgen-independent prostate cancer were imaged with 18F-FDG, 11CO, and 15O water before and during (mean interval 63 days, range 55-76 days) thalidomide therapy (200-1200mg/day). Lesions were visually identified on FDG images (9 bone, 5 soft tissue lesions). VOI's were generated by 3D region growing, with a 50{\%} maximum pixel threshold. These VOI's were registered with, and applied to, the 11CO and water studies. Correlations with PSA values were done using the Spearman rank test. The change in maximum (r = 0.77, P = 0.06) and mean FDG value (r = 0.83, P = 0.03), functional FDG volume (r = 0.66, P = 0.14), and 11-CO blood volume (r = 0.77, P = 0.06) all correlated with the change in PSA. Changes in blood flow values were smaller than the variance of the method for repeated measures, likely due to low flow values in bone. Changes in blood volume measured by 11CO, and the mean and peak activity and functional volume measured by 18F-FDG, correlate with changes in PSA and may be useful in monitoring anti-angiogenic therapy in prostate cancer.",
author = "Kurdziel, {K. A.} and Bacharach, {S. L.} and Carrasquillo, {J. A.} and S. Huebsch and M. Whatley and D. Sellers and S. Steinberg and Libutti, {S. K.} and J. Pluda and E. Reed and W. Dahut and Figg, {W. D.}",
year = "2000",
doi = "10.1016/S1095-0397(00)00056-X",
language = "English (US)",
volume = "3",
pages = "144",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Using PET 18F-FDG, 11CO, and 15O-water for monitoring prostate cancer during a phase II anti-angiogenic drug trial with thalidomide

AU - Kurdziel, K. A.

AU - Bacharach, S. L.

AU - Carrasquillo, J. A.

AU - Huebsch, S.

AU - Whatley, M.

AU - Sellers, D.

AU - Steinberg, S.

AU - Libutti, S. K.

AU - Pluda, J.

AU - Reed, E.

AU - Dahut, W.

AU - Figg, W. D.

PY - 2000

Y1 - 2000

N2 - Assessing prostate metastases is difficult with conventional radiographic modalities as few patients have soft tissue involvement and most have only bone lesions. Even with FDG PET, problems due to decreased avidity compared to other tumor types can occur. We assessed PET's ability to monitor changes in such tumors during an anti-angiogenic therapy. We measured changes in tumor blood flow (15O), blood volume (11CO), 18F-FDG uptake and "metabolic volume" before and during thalidomide treatment, to see if these changes correlated with changes in PSA values. Six patients with androgen-independent prostate cancer were imaged with 18F-FDG, 11CO, and 15O water before and during (mean interval 63 days, range 55-76 days) thalidomide therapy (200-1200mg/day). Lesions were visually identified on FDG images (9 bone, 5 soft tissue lesions). VOI's were generated by 3D region growing, with a 50% maximum pixel threshold. These VOI's were registered with, and applied to, the 11CO and water studies. Correlations with PSA values were done using the Spearman rank test. The change in maximum (r = 0.77, P = 0.06) and mean FDG value (r = 0.83, P = 0.03), functional FDG volume (r = 0.66, P = 0.14), and 11-CO blood volume (r = 0.77, P = 0.06) all correlated with the change in PSA. Changes in blood flow values were smaller than the variance of the method for repeated measures, likely due to low flow values in bone. Changes in blood volume measured by 11CO, and the mean and peak activity and functional volume measured by 18F-FDG, correlate with changes in PSA and may be useful in monitoring anti-angiogenic therapy in prostate cancer.

AB - Assessing prostate metastases is difficult with conventional radiographic modalities as few patients have soft tissue involvement and most have only bone lesions. Even with FDG PET, problems due to decreased avidity compared to other tumor types can occur. We assessed PET's ability to monitor changes in such tumors during an anti-angiogenic therapy. We measured changes in tumor blood flow (15O), blood volume (11CO), 18F-FDG uptake and "metabolic volume" before and during thalidomide treatment, to see if these changes correlated with changes in PSA values. Six patients with androgen-independent prostate cancer were imaged with 18F-FDG, 11CO, and 15O water before and during (mean interval 63 days, range 55-76 days) thalidomide therapy (200-1200mg/day). Lesions were visually identified on FDG images (9 bone, 5 soft tissue lesions). VOI's were generated by 3D region growing, with a 50% maximum pixel threshold. These VOI's were registered with, and applied to, the 11CO and water studies. Correlations with PSA values were done using the Spearman rank test. The change in maximum (r = 0.77, P = 0.06) and mean FDG value (r = 0.83, P = 0.03), functional FDG volume (r = 0.66, P = 0.14), and 11-CO blood volume (r = 0.77, P = 0.06) all correlated with the change in PSA. Changes in blood flow values were smaller than the variance of the method for repeated measures, likely due to low flow values in bone. Changes in blood volume measured by 11CO, and the mean and peak activity and functional volume measured by 18F-FDG, correlate with changes in PSA and may be useful in monitoring anti-angiogenic therapy in prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0000956889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0000956889&partnerID=8YFLogxK

U2 - 10.1016/S1095-0397(00)00056-X

DO - 10.1016/S1095-0397(00)00056-X

M3 - Article

AN - SCOPUS:0000956889

VL - 3

SP - 144

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 4

ER -